Publications


“Structure of Plasmodium falciparum Rh5–CyRPA–Ripr invasion complex”

Abstract: Plasmodium falciparum causes the severe form of malaria that has high levels of mortality in humans. Blood-stage merozoites of P. falciparuminvade erythrocytes, and this requires interactions between multiple ligands from the parasite and receptors in hosts. These interactions include the binding of the Rh5–CyRPA–Ripr complex with the erythrocyte receptor basigin1,2, which […]


“Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody”

Abstract: The quest to develop an effective malaria vaccine remains a major priority in the fight against global infectious disease. An approach with great potential is a transmission-blocking vaccine which induces antibodies that prevent establishment of a productive infection in mosquitos that feed on infected humans, thereby stopping the transmission […]


“Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells”

Abstract: Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under cGMP using the ExpreS2 platform (based on a Drosophila melanogaster S2 stable cell line […]


“Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies”

The ExpreS2 system was used for the production of recombinant PvDBP_RII (SalI) protein for ELISA-based assays in the article “Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies” Abstract BACKGROUND. Plasmodium vivax is the most widespread human malaria geographically; however, no effective vaccine exists. Red blood cell invasion by […]


“Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’”

The ExpreS2 system was used in the production of  the recombinant protein produced in the study “Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’” Abstract Development of bespoke biomanufacturing processes remains a critical bottleneck for translational studies, in particular when […]


The ExpreS2 system used in a new study published in Vaccine “Comparison of functional assays used in the clinical development of a placental malaria vaccine”

The article “Comparison of functional assays used in the clinical development of a placental malaria vaccine” was recently published in Vaccine. Abstract BACKGROUND: Malaria in pregnancy is associated with significant morbidity in pregnant women and their offspring. Plasmodium falciparum infected erythrocytes (IE) express VAR2CSA that mediates binding to chondroitin sulphate A […]


The ExpreS2 system is used for production of full-length soluble Plasmodium falciparum RH5 protein vaccine

The article “Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system” was recently published in Scientific Reports. Abstract The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has recently emerged as a leading candidate antigen against the blood-stage human malaria parasite. However […]


ExpreS2ion Biotechnologies contributes to scientific article

ExpreS2ion Biotechnologies’ scientists contributed to the research for the article by Thrane et al, ”Bacterial superglue enables easy development of efficient virus-like particle based vaccines”, which is published in the Journal of Nanobiotechnology, on 27th April, 2016. The article documents an exciting VLP vaccine platform enabling the binding of complex […]


The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine.

“The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine” by using the ExpreS2 technology platform compliant with clinical development. Read the article